Screener
SG&A at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Denali Therapeutics Inc. in its filing.
Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.
The source filing: Denali Therapeutics Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:08 PM EDT
- Fiscal quarter
- Q4 FY2026
- Calendar quarter
- Q4 2026
- Accession
- 0001714899-26-000097
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Operating expenses: | ||||
| Cost of goods sold | 93 | — | 93 | — |
| Research and development | 97,019 | 102,696 | 200,865 | 218,923 |
| Selling, general and administrative | 36,283 | 32,267 | 69,794 | 61,620 |
| Intangible asset amortization | 750 | — | 750 | — |
| Total operating expenses | 134,145 | 134,963 | 271,502 | 280,543 |
| Loss from operations | (130,541) | (134,963) | (267,898) | (280,543) |
| Interest and other income, net | 2,988 | 10,844 | 11,898 | 23,454 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Denali Therapeutics Inc.'s SG&A?
- Denali Therapeutics Inc. (DNLI) reported SG&A of $36.28M in Q2 2026.
- What does SG&A mean?
- Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.
Ask your AI about Denali Therapeutics Inc.'s sg&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude